JAZZ vs. TMO: Jazz Pharmaceuticals vs. Thermo Fisher Scientific Stock Comparison

Company Profile

Jazz Pharmaceuticals (JAZZ) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JAZZ is classified in Pharmaceuticals while TMO is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Thermo Fisher Scientific (TMO) at 13.38% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for TMO.

Thermo Fisher Scientific (TMO) at 14.94% retains a top-quartile share of revenue as profit, ahead of Jazz Pharmaceuticals (JAZZ) at 4.37%, which keeps about the industry-typical share.

Both Jazz Pharmaceuticals (JAZZ) at 30.17% and Thermo Fisher Scientific (TMO) at 20.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Jazz Pharmaceuticals (JAZZ) at 4.88% and Thermo Fisher Scientific (TMO) at 3.91% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Thermo Fisher Scientific (TMO) at 7.32% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.

Growth Metrics

Financial Strength

Both Jazz Pharmaceuticals (JAZZ) at 1.82 and Thermo Fisher Scientific (TMO) at 1.81 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Jazz Pharmaceuticals (JAZZ) at 1.35 and Thermo Fisher Scientific (TMO) at 0.75 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.

Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.

Dividend Metrics

Valuation

Thermo Fisher Scientific (TMO) at 36.64 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Jazz Pharmaceuticals (JAZZ) at 3.19 and Thermo Fisher Scientific (TMO) at 5.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Jazz Pharmaceuticals (JAZZ) at 3.59 and Thermo Fisher Scientific (TMO) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics